



Agenda

DAY 1 THURSDAY – JANUARY 30

2:00-2:10pm	Welcome and introduction	Owen A. O'Connor (USA)
2:10-2:15	Introduction of keynote presenter	Stephen M. Ansell (USA)
2:15-3:00	Keynote address:	James P. Allison (USA)

SESSION 1: Novel Immunologic Approaches and Consideration in PTCL Treatment

Moderators:		
3:05-3:20	Immune therapy for T cell lymphoma- where are we?	Stephen M. Ansell (USA)
3:25-3:40	Predictive Immunologic biomarkers in PTCL: From Programmed Death Ligand to PDL-1 and TLR5	Won Seog Kim (Korea)
3:45-4:00	Single agent checkpoint blockade in PTCL: From activity to biomarkers of response	Stefan Barta (USA)
4:05-4:20	CAR T vs TAA-T in in PTCL	Catherine Bollard (USA)
4:25-4:40	Break/Exhibits	

SESSION 2: CTCL and PLL

Moderators:		
4:45-5:00	New pathways, new targets for CTCL	Madeleine Duvic (USA)
5:05-5:20	Update on clinical assessment of CTCL	Elise Olsen (USA)
5:25-5:40	Gene expression and new prognostic indicators in CTCL	Ivan Litvinov (Ottawa)
5:45-6:00	Update on T-PLL	Claire Dearden (UK)
6:05-9:00	Welcome Dinner	

DAY 2 FRIDAY – JANUARY 31

7:00-8:00	Breakfast Symposium	
8:10-8:15	Day 2 opening remarks:	

SESSION 3: What's New in TCL

Moderators:		
8:15-8:30	Can identification of oncogenic drivers in PTCL lead to new drug targets?	Ryan Wilcox (USA)
8:35-8:50	The emerging spectrum of hypomethylating agents: It's not so simple anymore	Jennifer Lue (CU)
8:55-9:10	The merits of high-throughput screening approaches in PTCL: Will it translate to the clinic?	Wei Ai (USA)
9:15-9:30	Mutations in TIM-3 in Panniculitis like T cell lymphoma	TBD
9:35-9:50	Targeting CD47 in PTCL: From rationale to evidence	Irving Weissman (USA)
9:55-10:10	Chronic EBV LPd	Kimura Hiroshi (Japan)
10:15-10:30	Break/Exhibits	

SESSION 4: Novel mouse models of TCL

Moderators:		
10:30-10:45	A Review of Mouse Models of PTCL	Christine E. Cutucache (USA)
10:50-11:05	Spontaneous genetically engineered mouse models of PTCL (not including AITL)	Adolfo Ferrando (USA)
11:10-11:25	Mouse Models of AITL: The Pros and Cons of Established Models	Fujisawa Manabu (Japan)
11:30-11:45	LGL Mouse Model: A Practical Tool for Drug Development?	Thomas Loughran (USA)
11:50-12:05	T-Cell Lymphomas in Dogs: The Merits of Spontaneous Canine Models	David Vail (USA)
12:10-12:30	Lunch	



12:30-1:30	Luncheon Symposium	
SESSION 5: Make the Case		
Moderators:		
1:45-2:30	Chidamide-CHOP new standard in China	Wei-li Zhao (China)
2:30-2:50	Incorporating new agents up front: - Is brentuximab CHP the new standard? - Are we ready to change treatment paradigm?	Barbara Pro (USA) Steven Horwitz (USA)
2:50-3:20	<i>Audience participation/discussion</i>	
3:20-3:40	Auto or Allo in 1st Remission: - Always or Sometimes - Never	Paolo Corradini (Italy) Francesco D'Amore (Sweden)
3:40-3:55	<i>Audience participation/discussion</i>	
	Break/Exhibits	
SESSION 6: Issues in Clinical Management		
Moderators:	Francine M. Foss, Won Seog Kim, Owen A. O'Connor	
3:55-4:10	Managing HTLV-1 associated lymphomas in the new era- how to incorporate new agents	Juan C. Ramos (USA)
4:15-4:30	The Diagnostic and Prognostic Merits of PET in PTCL	Domenico Rubello (Italy)
4:35-4:50	CNS Prophylaxis in PTCL: Who, When, Why	Dejan Radeski (Australia)
4:55-5:10	What's new with Breast Associated ALCL	Miles Prince (Australia)
SESSION 7: Poster presentations (10-minute presentations; no Q&A)		
Moderators:	Francine M. Foss, Won Seog Kim, Owen A. O'Connor	
5:12-5:22	1.	
5:24-5:34	2.	
5:36-5:46	3.	
5:48-5:58	4.	
6:00-6:10	5.	
6:12-6:22	6.	
6:22-8:00	Poster Walk Reception/Exhibits	
DAY 3 SATURDAY – FEBRUARY 1		
7:00-8:00am	Breakfast Symposium	
8:10-8:15am	Day 3 opening remarks:	
SESSION 8: International Guidelines on the Treatment of PTCL: Are We Closer to Global Standard of Care		
Moderators:		
8:15-8:30	USA	Julie Vose (USA)
8:35-8:50	Europe	Pier Luigi Zinzani (Italy)
8:55-9:10	Canada	Kerry Savage (Canada)
9:15-9:30	China	Jun Ma (China)
9:35-9:50	Australia	
9:55-10:10	Japan	Michinori Ogura (Japan)
10:15-10:30	South America	Carlos Chiattonne (Brazil)
10:35-10:50		
10:55-11:10	Break/Exhibits	



SESSION 9: Industry Innovations

Moderators: Francine M. Foss, Won Seog Kim, Owen A. O'Connor

11:10-11:25	Portola/Miragen	
11:30-11:45	Biomarker Driven Phase 3 Studies Are Our Best Hope for Success: DeNovo	Wen Luo
11:50-12:05	Targeting clAP in the T-Cell Lymphomas: The next new drug? (Astex)	Martin Sims
12:10-12:25	NK-Engagers (Affimed)	Germany Rep
12:30-12:45	CAR Engineered Macrophages: Myeloid IN (Cour Pharmaceuticals)	Daniel Getts
12:45-1:00	Box Lunch	

SESSION 10: Wrap-up Highlights

Moderators: Francine M. Foss, Won Seog Kim, Owen A. O'Connor

1:10-1:20	Summary perspective on CTCL	Pierluigi Porcu (USA)
1:20-1:30	Summary perspective on PTCL	Francine Foss (USA)
1:30-1:40	Registry Update	Massimo Federico (Italy)
1:40-1:45	Status of International Collaborations	Owen O'Connor (USA)
1:45-1:55	Closing remarks	
2:00	Meeting adjourns	